Stem cell com­pa­ny bit.bio cuts quar­ter of staff, drops ther­a­peu­tics fo­cus

The British stem cell com­pa­ny bit.bio has re­duced its work­force by 25%, im­pact­ing most of the ther­a­peu­tics di­vi­sion, founder and board mem­ber Mark Kot­ter con­firmed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER